These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
213 related articles for article (PubMed ID: 30806748)
21. Tolerance and efficacy of BRAF plus MEK inhibition in patients with melanoma who previously have received programmed cell death protein 1-based therapy. Saab KR; Mooradian MJ; Wang DY; Chon J; Xia CY; Bialczak A; Abbate KT; Menzies AM; Johnson DB; Sullivan RJ; Shoushtari AN Cancer; 2019 Mar; 125(6):884-891. PubMed ID: 30521084 [TBL] [Abstract][Full Text] [Related]
23. Dabrafenib plus trametinib versus dabrafenib monotherapy in patients with metastatic BRAF V600E/K-mutant melanoma: long-term survival and safety analysis of a phase 3 study. Long GV; Flaherty KT; Stroyakovskiy D; Gogas H; Levchenko E; de Braud F; Larkin J; Garbe C; Jouary T; Hauschild A; Chiarion-Sileni V; Lebbe C; Mandalà M; Millward M; Arance A; Bondarenko I; Haanen JBAG; Hansson J; Utikal J; Ferraresi V; Mohr P; Probachai V; Schadendorf D; Nathan P; Robert C; Ribas A; Davies MA; Lane SR; Legos JJ; Mookerjee B; Grob JJ Ann Oncol; 2017 Jul; 28(7):1631-1639. PubMed ID: 28475671 [TBL] [Abstract][Full Text] [Related]
24. Outcomes after progression of disease with anti-PD-1/PD-L1 therapy for patients with advanced melanoma. Patrinely JR; Baker LX; Davis EJ; Song H; Ye F; Johnson DB Cancer; 2020 Aug; 126(15):3448-3455. PubMed ID: 32463489 [TBL] [Abstract][Full Text] [Related]
25. Clinical and economic outcomes associated with treatment sequences in patients with BRAF-mutant advanced melanoma. Tarhini A; McDermott D; Ambavane A; Gupte-Singh K; Aponte-Ribero V; Ritchings C; Benedict A; Rao S; Regan MM; Atkins M Immunotherapy; 2019 Mar; 11(4):283-295. PubMed ID: 30563395 [TBL] [Abstract][Full Text] [Related]
26. Comparison of dabrafenib and trametinib combination therapy with vemurafenib monotherapy on health-related quality of life in patients with unresectable or metastatic cutaneous BRAF Val600-mutation-positive melanoma (COMBI-v): results of a phase 3, open-label, randomised trial. Grob JJ; Amonkar MM; Karaszewska B; Schachter J; Dummer R; Mackiewicz A; Stroyakovskiy D; Drucis K; Grange F; Chiarion-Sileni V; Rutkowski P; Lichinitser M; Levchenko E; Wolter P; Hauschild A; Long GV; Nathan P; Ribas A; Flaherty K; Sun P; Legos JJ; McDowell DO; Mookerjee B; Schadendorf D; Robert C Lancet Oncol; 2015 Oct; 16(13):1389-98. PubMed ID: 26433819 [TBL] [Abstract][Full Text] [Related]
27. Upcoming strategies for the treatment of metastatic melanoma. Spagnolo F; Queirolo P Arch Dermatol Res; 2012 Apr; 304(3):177-84. PubMed ID: 22350184 [TBL] [Abstract][Full Text] [Related]
28. Mechanisms of Resistance to BRAF-Targeted Melanoma Therapies. Dulgar O; Kutuk T; Eroglu Z Am J Clin Dermatol; 2021 Jan; 22(1):1-10. PubMed ID: 33368052 [TBL] [Abstract][Full Text] [Related]
39. First-line immunotherapy versus targeted therapy in patients with Pavlick AC; Zhao R; Lee CH; Ritchings C; Rao S Future Oncol; 2021 Feb; 17(6):689-699. PubMed ID: 33084375 [No Abstract] [Full Text] [Related]
40. Combination Treatment of Patients with BRAF-Mutant Melanoma: A New Standard of Care. Simeone E; Grimaldi AM; Festino L; Vanella V; Palla M; Ascierto PA BioDrugs; 2017 Feb; 31(1):51-61. PubMed ID: 28058658 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]